((Automated translation by Reuters, please see disclaimer https://bit.ly/rtrsauto))
(Added comments from Rovi to paragraphs 1,2)
Rovi ROVI.MC has received non-binding offers for its third-party manufacturing business, the Spanish pharmaceutical company said on Wednesday, without disclosing the names of the bidders.
No final decision has been made on the potential sale, Rovi said in a document submitted to the securities regulator.
The Antin investment funds ANTIN.PA, Cinven, CVC
CVC.AS, KKR KKR.N and Permira have submitted offers, Expansion newspaper reported earlier on Wednesday.
The five companies submitted non-binding offers on June 13 and are now in the middle of a due diligence process for the binding offers, the newspaper reported.
Spokespeople for Cinven and KKR declined to comment, while Antin, CVC and Permira did not immediately respond to requests for comment.
Rovi said in March it had hired Lazard LAZ.N as an advisor on the potential sale of a company that produced COVID-19 vaccines on behalf of Moderna
MRNA.O, among other medications.
The value of the sale is estimated at around 3.5 billion euros ($3.75 billion), according to Expansion.
($1 = 0.9344 euros)